

PERSONAL INFORMATION

Selene Baschieri

ENEA SSPTT-BIOAG-BIOTEC
 C.R. Casaccia, Via Anguillarese 301, 00123 Roma
 Email Address: selene.baschieri@enea.it Tel: +390630486612
 Sex: F Date of birth: 09/04/1964 Nationality: Italian



| Enterprise | University | EPR |
|--|--|---|
| <input type="checkbox"/> Management Level | <input type="checkbox"/> Full professor | <input checked="" type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator |
| <input type="checkbox"/> Mid-Management Level | <input type="checkbox"/> Associate Professor | <input type="checkbox"/> Level III Researcher and Technologist |
| <input type="checkbox"/> Employee / worker level | <input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator | <input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator |

WORK EXPERIENCE

from 1990 - to now ENEA, Italian National Agency for New Technologies, Energy and Sustainable Economic Development, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy

EDUCATION AND TRAINING

from 1990- to 1991 **Rusconi Foundation fellowship** Ludwig Institute for Cancer Research at Epalinges, Switzerland, under the supervision of H.R. MacDonald
 ▪ mechanisms involved in central and peripheral immunological tolerance

from 1989- to 1990 **Adriano-Buzzati Traverso fellowship** ENEA C.R. Casaccia
 ▪ Experimental immunology

from 1988- to 1990 **Adriano-Buzzati Traverso fellowship** ENEA C.R. Casaccia
 ▪ Experimental immunology

26 May 1987 **Biological Sciences (magna cum laude)** La sapienza University, Rome

WORK ACTIVITIES

from 2023 - to now Coordinator of the project “An integrated biotechnological approach for the development of celiac-safe flours with high technological properties (BIOGLUSAFE)” funded by ENEA Proof of Concept Program.

from 2022 - to now Coordinator of the international project “Next-generation vaccines and diagnostics to prevent livestock reproductive diseases of worldwide impact” (REPRODIVAC) funded within the European framework Horizon Europe, HORIZON-CL6-2021-FARM2FORK-01-06: Vaccines and diagnostics for priority animal diseases.

from 2019 - to 2020 Coordinator of the project “An integrated biotechnological approach for the development of celiac-safe flours with high technological properties (BIOGLUSAFE)” funded by ENEA Proof of Concept Program.

from 2017 - to 2023 Partner of the project “Plant virus nanoparticles for blood brain barrier crossing and medulloblastoma targeting (NANOCROSS)” funded by the Italian Foundation for Cancer Research (AIRC, Associazione Italiana per la Ricerca sul Cancro).

from 2016 - to 2020 Coordinator of the transnational project “AVIAn viral disease prevention and control with plant vaccines for the MEDiterranean area (AVIAMED)” selected for funding by the Eranet ARIMNET2.

from 2001 - to now Identification of new strategies for the use of plants as biofactories for biomolecules and plant viruses for applications in biomedicine and the development of new materials.

from 1994 - to 2001 Cloning and expression in *Escherichia coli* the cDNA encoding the major allergen of *Parietaria judaica*. Study of the alteration in the control of N-linked glycosylation in the congenital anaemia HEMPAS (Hereditary Erythroblastic Multinuclearity with Positive Acidified Serum lysis test).

from 1990 - to 1991 Mechanisms of central and peripheral tolerance in the group of Dr H.R. MacDonald to the Ludwig Institute of Cancer Research (Lausanne Branch) (Switzerland).

from 1987 - to 1994

Effects of aging and ionizing radiation on T cell development and of the mechanisms involved in central and peripheral immunological tolerance.

PERSONAL SKILLS

Mother tongue

Italian

Other languages

Excellent knowledge of French and English

ADDITIONAL INFORMATION

Publications and main indexes

Total number of publications in peer-review journals: 49

H-Index: 19

Google Scholar Page: [selene baschieri - Google Scholar](#)Scopus: [Baschieri, Selene - Author details - Scopus](#)

Publons:

ORCID: [Selene Baschieri \(0000-0001-7147-7840\) \(orcid.org\)](#)

Relevant publications for the call (max 5)

Grinzato A., Kandiah E., Lico C., Betti C., **Baschieri S.**, Zanotti G. Atomic structure of Potato virus X, the prototype of the Alphaflexiviridae family. *Nature Chemical Biology* 16:564-569, 2020.

Lico C., Giardullo P., Mancuso M., Benvenuto E., Santi L., **Baschieri S.** A biodistribution study of two differently shaped plant virus nanoparticles reveals new peculiar traits. *Colloids and Surfaces B: Biointerfaces* 148:431-439, 2016.

Blandino A., Lico C., **Baschieri S.**, Barberini L., Cirotto C., Blasi P., Santi L. In vitro and in vivo toxicity evaluation of plant virus nanocarriers. *Colloids and Surfaces B: Biointerfaces* 129:130-136, 2015.

Betti C., Lico C., Maffi D., D'Angeli S., Altamura M.M., Benvenuto E., Faoro F., **Baschieri S.** Potato virus X movement in *Nicotiana benthamiana*: new details revealed by chimeric coat protein variants. *Molecular Plant Pathology* 13: 198-293, 2012.

Lico C., Mancini C., Italiani P., Betti C., Boraschi D., Benvenuto E., **Baschieri S.** Plant-produced Potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. *Vaccine* 27: 5069-5076, 2009.

Presentations at conferences

Over 70 abstracts in conference proceedings of which more than 20 selected for oral presentation

Main projects with interest for the call (last 5 years)

"Next-generation vaccines and diagnostics to prevent livestock reproductive diseases of worldwide impact" (REPRODIVAC) Horizon Europe, HORIZON-CL6-2021-FARM2FORK-01-06: Vaccines and diagnostics for priority animal diseases.

"AVian viral disease prevention and control with plant vaccines for the MEDiterranean area (AVIAMED)" (ERAnet ARIMNET2)

"Plant virus nanoparticles for blood brain barrier crossing and medulloblastoma targeting (NANOCROSS)" (AIRC, Associazione Italiana per la Ricerca sul Cancro, Italian Foundation for Cancer Research)

Date

Signature

November the 23rd 2022